Australia - English - Department of Health (Therapeutic Goods Administration)

generic health pty ltd - oxytocin, quantity: 10 iu/ml - injection, solution - excipient ingredients: sodium chloride; glacial acetic acid; sodium acetate; water for injections - induction of labour; inadequate uterine effort; management of third stage of labour; post-partum haemorrhage.

Australia - English - Department of Health (Therapeutic Goods Administration)

generic health pty ltd - oxytocin, quantity: 5 iu/ml - injection, solution - excipient ingredients: water for injections; sodium acetate; sodium chloride; glacial acetic acid - induction of labour; inadequate uterine effort; management of third stage of labour; post-partum haemorrhage.

Australia - English - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - oxytocin, quantity: 5 iu - injection, solution - excipient ingredients: glacial acetic acid; sodium acetate trihydrate; water for injections; sodium hydroxide - oxytocin is indicated for the induction of labour; inadequate uterine effort; management of third stage of labour; post-partum haemorrhage.

Australia - English - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - oxytocin, quantity: 10 iu - injection, solution - excipient ingredients: glacial acetic acid; sodium acetate trihydrate; water for injections; sodium hydroxide - oxytocin is indicated for the induction of labour; inadequate uterine effort; management of third stage of labour; post-partum haemorrhage.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - oxytocin -

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - oxytocin -

Australia - English - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - ciclosporin, quantity: 50 mg/ml - injection, concentrated - excipient ingredients: ethanol; peg-35 castor oil - this product is accepted for registration as 'currently supplied' at the time of commencement of the act. new indications were approved as specified in the letter of 16 june 1992 from dr l. hunt. indications: as an immunosuppressive agent for the prevention of graft rejection following kidney, liver and heart allogeneic transplantation. extended indications as at 15 october 1993: for induction and/or maintenance of remission in the nephrotic syndrome. cyclosporin is not a first-line agent. its use should be restricted to occasions when steroids and cytostatic drugs have failed, or are not tolerated, or are considered inappropriate, and when renal function is unimpaired . indications as at 11 february 1994 from dr j. mcginness: 1. as an immunosuppressive agent for the prevention of graft rejection following kidney, liver and heart allogeneic transplantation. 2. for induction and/or maintenance of remission in the nephrotic syndrome. cyclosporin is not a first-line agent. its use should be restricted to occas

Canada - English - Health Canada

astellas pharma canada inc - adenosine - solution - 3mg - adenosine 3mg - miscellaneous therapeutic agents

Canada - English - Health Canada

astellas pharma canada inc - adenosine - solution - 3mg - adenosine 3mg - miscellaneous therapeutic agents